The role and therapeutic implications of T cells in cancer of the lung
Authors:
Open Access
- 1 January 2019
- journal article
- review article
- Published by Wiley in Clinical & Translational Immunology
- Vol. 8 (8) , e1076
Abstract
Lung cancer remains the leading cause of cancer‐related death worldwide. The disease is classified into two major subtypes, small‐cell lung cancer (SCLC) and the more prevalent non‐small‐cell lung cancer (NSCLC). First‐line conventional therapies, such as chemotherapy, radiotherapy and surgery, have offered limited benefit, and patient prognosis remains poor with post‐treatment recurrences representing a major cause of morbidity. Consequently, there is an urgent need for improved therapeutic options. Historically, NSCLC has been considered a non‐immunogenic disease. However, increased understanding of tumor‐immune interactions has challenged this paradigm in both lung and other malignancies, with cancer elimination by tumor‐specific T cells increasingly well described in a myriad of solid tumors. Recent evidence has demonstrated that absent or weak anticancer responses are likely a product of tumor‐derived immunosuppression. This knowledge, along with a greater appreciation for the role of T cells in lung cancer elimination, has driven development of novel immunotherapeutic approaches which are demonstrating remarkable clinical efficacy. This review examines the role of T cells in lung cancer, discussing the direction and clinical significance of current and future immunotherapeutic strategies.Keywords
This publication has 60 references indexed in Scilit:
- Agonistic Anti-CD40 Antibody Therapy is Effective Against Postoperative Cancer Recurrence and Metastasis in a Murine Tumor ModelJournal of Immunotherapy, 2013
- Treatment of Stage I and II Non-small Cell Lung CancerChest, 2013
- Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumorsOncoImmunology, 2013
- Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentationOncoImmunology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Natural Innate and Adaptive Immunity to CancerAnnual Review of Immunology, 2011
- The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu miceCancer Immunology, Immunotherapy, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- CTLA-4: new insights into its biological function and use in tumor immunotherapyNature Immunology, 2002